Thorax 64:1004 doi:10.1136/thx.2009.122887
  • Miscellaneous
  • Lung alert

Diarylquinoline TMC207 as potential new therapy for multidrug-resistant tuberculosis

  1. E Tevendale
  1. Correspondence to Dr E Tevendale, CMT1, St James University Hospital, Leeds, UK; ewantevendale{at}

    TMC207 is an investigational diarylquinoline which inhibits mycobacterial ATP synthase in drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro. It is bactericidal to dormant tubercle bacilli, therefore offering a new mechanism for the treatment of multidrug-resistant tuberculosis.

    This study is the first stage of a phase 2 randomised controlled trial. Conducted in South Africa, newly …

    Free sample
    This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Thorax.
    View free sample issue >>

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

    Navigate This Article